FOLETTA MARK G 4

What Happened

• Mark G. Foletta, a director of DexCom, was granted 6,331 restricted stock units (RSUs) on May 28, 2026 (transaction code A — Award). The RSUs were granted at $0.00 (no cash paid). Each RSU represents a contingent right to receive one share of DexCom common stock upon settlement.

Key Details

• Transaction date: 2026-05-28 (reported on Form 4 filed 2026-06-01) — filing appears timely (within the SEC two-business-day window).
• Amount and price: 6,331 RSUs granted @ $0.00 (award/grant).
• Vesting: 100% of the RSU award vests on the earlier of the one-year anniversary of the grant (May 28, 2027) or DexCom’s 2027 Annual Meeting of Stockholders (per footnote).
• Shares after transaction: Not specified in the provided filing details.
• Ownership vehicle: Shares are held by The Foletta Family Trust DTD 1/30/2015; Mark G. Foletta is a trustee (footnote).
• Filing note: No tax withholding, sale, or exercise reported in this filing.

Context

• This was a compensation award (RSUs), not a purchase or sale; such grants are routine director compensation and do not, by themselves, indicate immediate buying or selling of shares.
• Upon vesting and settlement, each RSU will convert into one share of common stock; timing depends on the vesting condition described above.